Modifying mesenchymal stem cells (MSCs) — a type of stem cell found in various tissues and, in this case,…
Articles by Andrea Lobo, PhD
The first patient with systemic sclerosis (SSc) has been dosed in a Phase 1 trial of Adicet Bio’s…
The Scleroderma Research Foundation (SRF) announced that it has joined Vie Ventures to advance research and accelerate the…
Most people with systemic sclerosis (SSc) have fibrosis, or scarring, that affects the heart muscle, a study in Australia…
Lung function decline among people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) was significantly slowed over the course of about…
Wasting of the skeletal muscle, older age, being male, and having swollen joints are among the risk factors for primary…
People older than 65 and women are more likely to develop localized scleroderma, a study in the U.S. shows.The…
Women have a nearly fivefold higher risk of developing systemic sclerosis (SSc), according to the findings of a nationwide…
A Phase 1/2 trial testing Cabaletta Bio’s CAR T-cell therapy, rese-cel (resecabtagene autoleucel), in adults with hard-to-treat systemic…
Treatment with Ofev (nintedanib) for up to four years was associated with a sustained slowing of lung function decline…